On Friday, Aclaris Therapeutics Inc (NASDAQ: ACRS) was 31.01% up from the session before settling in for the closing price of $1.29. A 52-week range for ACRS has been $0.59 – $5.70.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 74.29% over the last five years. When this article was written, the company’s average yearly earnings per share was at 56.36%. With a float of $67.49 million, this company’s outstanding shares have now reached $70.89 million.
The firm has a total of 91 workers. Let’s measure their productivity. In terms of profitability, gross margin is 65.56%, operating margin of -193.06%, and the pretax margin is -184.43%.
Aclaris Therapeutics Inc (ACRS) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Aclaris Therapeutics Inc stocks. The insider ownership of Aclaris Therapeutics Inc is 5.40%, while institutional ownership is 73.00%. The most recent insider transaction that took place on Aug 05 ’24, was worth 256,357. In this transaction 10% Owner of this company bought 206,025 shares at a rate of $1.24, taking the stock ownership to the 14,250,000 shares. Before that another transaction happened on Aug 02 ’24, when Company’s 10% Owner bought 167,544 for $1.29, making the entire transaction worth $216,400. This insider now owns 14,043,975 shares in total.
Aclaris Therapeutics Inc (ACRS) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 56.36% per share during the next fiscal year.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Trading Performance Indicators
You can see what Aclaris Therapeutics Inc (ACRS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 7.50. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.83, a number that is poised to hit -0.01 in the next quarter and is forecasted to reach -0.64 in one year’s time.
Technical Analysis of Aclaris Therapeutics Inc (ACRS)
Analysing the last 5-days average volume posted by the [Aclaris Therapeutics Inc, ACRS], we can find that recorded value of 1.72 million was better than the volume posted last year of 0.99 million. As of the previous 9 days, the stock’s Stochastic %D was 89.61%. Additionally, its Average True Range was 0.07.
During the past 100 days, Aclaris Therapeutics Inc’s (ACRS) raw stochastic average was set at 97.22%, which indicates a significant increase from 96.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 108.70% in the past 14 days, which was higher than the 65.04% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1982, while its 200-day Moving Average is $1.2031. Now, the first resistance to watch is $1.8450. This is followed by the second major resistance level at $2.0000. The third major resistance level sits at $2.2900. If the price goes on to break the first support level at $1.4000, it is likely to go to the next support level at $1.1100. Should the price break the second support level, the third support level stands at $0.9550.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Key Stats
There are 71,265K outstanding shares of the company, which has a market capitalization of 120.56 million. As of now, sales total 31,250 K while income totals -88,480 K. Its latest quarter income was 2,770 K while its last quarter net income were -10,990 K.
